MS Treatments
International Progressive MS Alliance e-News
April 18, 2021International Progressive MS Alliance e-News - March 2021 In this issue: • Read about the recent call to action to prioritise research on symptoms that matter most to people affected…read more
Mavenclad quickly reduces MRI lesions in early MS
March 22, 2021Mavenclad (cladribine) reduces the number and volume of lesions in patients at risk of multiple sclerosis (MS) after a first clinical demyelinating event, a study based on Phase 3 trial…read more
Neurology Research Review – Issue 71 – MS Special
March 8, 2021Special issue of Neurology Research Review, focusing specifically on MS.read more
Progressive MS breakthrough treatments – Webinar
March 8, 2021Funded by the International Progressive MS Alliance, a first-of-its-kind global research network aims to develop new, effective treatments for progressive MS.read more
Covid-19 in Ocrelizumab-treated people with Multiple Sclerosis
January 25, 2021This article, written by the Journal of Multiple Sclerosis and related disorders, (MSARD) includes data from clinical trials, post marketing safety surveillance and a US electronic medical records database, Optum.read more
Announcement: PHARMAC consultation: proposal to widen access and transition the process for funded access to multiple sclerosis treatments
November 27, 2020Pharmac have released public consultation on a proposal to widen access to funded multiple sclerosis treatments and transition access from the Multiple Sclerosis Treatment Assessment Committee (MSTAC) Panel to a…read more
New Data: Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis
November 3, 2020New data on the long term benefits of Ocrelizumab for PPMS has recently been published 29 October 2020 on the Lancet Ocrelizumab is currently funded for RRMS in New Zealand…read more
Biotin (MD1003) Fails to Prevent Disability Progression in Progressive MS Patients, Trial Shows
November 3, 2020Note: This article was originally published on www.multiplesclerosisnewstoday.com, written by Marta Figueiredo and fact checked by Patrícia Silva, PHD. MD1003, MedDay Pharmaceuticals’ high-dose biotin therapy, failed to significantly improve functional…read more
Exploring medicinal use of cannabis in a time of policy change in New Zealand
July 13, 2020Exploring patterns of medicinal cannabis use prior to implementation of the new Medicinal Cannabis Scheme (MCS) in New Zealand.read more
Mabs – The Secret Agents Fighting MS
June 4, 2019What do the MS treatments ocrelizumab, alemetuzumab and natalizumab (Ocrevus, Lemtrada, and Tysabri) have in common?read more
Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
February 13, 2019Study results published show a noticeably reduced risk for progression of upper extremity (UE) disability compared with placebo in patients with primary progressive multiple sclerosis (PPMS)read more
Interferon-Beta, Glatiramer Acetate Equally Effective for Relapsing-Remitting MS
February 13, 2019Interferon-Beta, Glatiramer Acetate Equally Effective for Relapsing-Remitting MSread more
CAN BLOOD STEM CELLS REBOOT THE IMMUNE SYSTEM?
November 7, 2017There is a great deal of scientific and community interest in the role that stem cells might play in treating MS. Stem cell therapy is a treatment that uses or targets stem…read more
DO ANTI-INFLAMMATORY DRUGS DELAY DISABILITY IN SECONDARY PROGRESSIVE MS?
November 7, 2017While there has been great progress in the development of effective treatments for relapsing remitting MS over the last 15 years, there has not been the same advances in treatments…read more
RELAPSING MS TREATMENT CLADRIBINE ON THE COMEBACK
November 7, 2017Cladribine, an oral treatment for relapsing remitting MS, previously approved in Australia, but subsequently withdrawn, is making a comeback.read more
FIRST TREATMENT FOR PRIMARY PROGRESSIVE MS APPROVED IN AUSTRALIA
September 11, 2017MS Research Australia has been reporting on every step that Ocrevus a new MS medication, has taken on its journey to become the first ever approved treatment for progressive MS…read more
BEGINNINGS OF A UNIQUE NEW APPROACH FOR TREATING MS
July 10, 2017Our blood brain barrier is an amazing part of the body that keeps the brain and spinal cord highly protected, allowing through only those cells and nutrients that are needed…read more
COMMON ACNE MEDICATION MAY HELP DELAY A DIAGNOSIS OF MS
June 19, 2017Canadian researchers have published their results of a clinical trial testing whether an antibiotic commonly used in the treatment of acne can help prevent a diagnosis of MS in people…read more
FDA approves Ocrelizumab for relapsing-remitting and primary progressive MS
April 3, 2017The American Food and Drug Administration (FDA) has approved OCREVUS™ (ocrelizumab) for the treatment of both relapsing and primary progressive forms of multiple sclerosis.read more